| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2816873c6868ac137b962d6a49451db9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e97a6c9478ed2aafbc825d9a2190bed8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bfbbd09049e08afc8b0995307edf77a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ad47e6703bd58a3de6aaf93fe483935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c64aa97aefcc8b6ee890d416a59bc61 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-282 |
| filingDate |
2009-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78c524cafa7cf1057c7e0ff46abb32ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aecfae63402b272a8103f9739c75ebb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7985155fcdb4764608a022dd1adb8a09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c64ef82fa4322b5070522a311c7bd8c9 |
| publicationDate |
2010-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010005344-A1 |
| titleOfInvention |
Nanosomal pharmaceutical form of a long acting preparation for treating hepatitis c (variants) |
| abstract |
The aim of the invention is to develop a preparation and the concrete forms thereof for effectively treating a hepatitis C virus by delivering to and localising pharmaceutically effective doses of medicinal agents in the main target organ (liver) and inside hepatic cells (hepatocytes). The inventive preparation comprises an active component complex containing glutathione and inosin taken in a ratio of 1:1 and cisplatin in a quantity of 0.05%, wherein said active component complex is immobilised by absorption on a polymer carrier in the form of polylactide glycolide nanoparticles. In the second variant, the active component complex contains only glutathione and inosin taken in a ratio of 1:1. |
| priorityDate |
2008-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |